Established in May 2026 in Wuhan's East Lake High-Tech Development Zone, Radlum Therapeutics is a wholly owned subsidiary of HiDiamond.

As the Group's dedicated R&D hub for radiopharmaceutical source innovation, Radlum Therapeutics focuses on precision oncology diagnostics and targeted therapies, developing proprietary theranostic radiopharmaceuticals.

Upholding the core value of "Drug innovation, illuminating hope for patients," we are committed to addressing unmet clinical needs and improving patients' quality of life. By building an end-to-end R&D platform—from molecular probes and radionuclide labeling to preclinical studies and translational development—Radlum Therapeutics strives to become a world-class innovator in the radiopharmaceutical sector.